Recent News

• 06.06.2025 - Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 06.06.2025 - Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 05.18.2025 - Seralutinib in Pulmonary Arterial Hypertension: Exploring Mechanisms of Reverse Remodeling Versus Vasodilation
• 05.15.2025 - Gossamer Bio Q1 2025 Earnings Call
• 05.15.2025 - Gossamer Bio Q1 2025 Earnings Call
• 05.15.2025 - Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study
• 05.15.2025 - Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study
• 05.12.2025 - Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025
• 05.12.2025 - Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025
• 05.07.2025 - Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 05.15.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.15.2025 - 8-K Current report
• 05.15.2025 - EX-99.1 EX-99.1
• 04.29.2025 - DEF 14A Other definitive proxy statements
• 04.29.2025 - ARS Annual Report to Security Holders
• 04.29.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material